Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Researchers sought to compare the effect of abelacimab vs rivaroxaban on risk for bleeding in patients with atrial fibrillation.

I’m a generally healthy 60-year-old man. Last week, I had some abdominal cramping, and while I was on the toilet, I noted the abrupt onset of a ...

I'm a generally healthy 60-year-old man. Last week, I had some abdominal cramping, and while I was on the toilet, I noted the ...

C, shares how she saved Dr Jacquelyn Lacera’s life from a near-fatal cardiovascular event while aboard a flight from Hawaii.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Current AF management guidelines have introduced the CARE treatment model to strengthen management ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a challenge for Milestone Pharmaceutical in its 22 years. | The FDA has rejected ...

Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...